Phase I clinical trial on intracoronary administration of Ad-hHGF treating severe coronary artery disease

@article{Yang2008PhaseIC,
  title={Phase I clinical trial on intracoronary administration of Ad-hHGF treating severe coronary artery disease},
  author={Zhi-jian Yang and You-rong Zhang and Bo Chen and Shu-lan Zhang and En-Zhi Jia and Lian-sheng Wang and Tie-bing Zhu and Chun-jian Li and Hui Wang and Jun Huang and Ke-jiang Cao and Wen-zhu Ma and Bin Wu and Li-Sheng Wang and Chu-Tse Wu},
  journal={Molecular Biology Reports},
  year={2008},
  volume={36},
  pages={1323-1329}
}
Objective Therapeutic angiogenesis is a new strategy for treatment of vascular insufficiency. Hepatocyte growth factor (HGF)-induced angiogenesis has been applied to induce the neovascularization of ischemic adult tissues in preclinical studies. This report summarizes a phase I clinical trial on the safety of adenovirus-mediated human HGF (Ad-HGF) gene transfer to treat clinically significant coronary artery disease. Methods The 18 patients with severe and diffused triple vessel disease… Expand
Gene therapy to stimulate angiogenesis to treat diffuse coronary artery disease.
TLDR
Overall, studies of gene therapy for ischemia in experimental models are very encouraging, with clear evidence of safety and efficacy, strongly supporting the concept that gene therapy to induce angiogenesis is a viable therapeutic approach for CAD. Expand
Safety and Efficacy of Intracoronary Ad-HGF Administration for Treating Severe Coronary Disease: Results From Long-Term Follow-Up of a Phase I Clinical Trial
Objective: This study is a long-term follow-up of our previous phase I clinical trial and aims at evaluating the long-term safety and efficacy of intracoronary Ad-HGF administration for treatingExpand
Long-term follow-up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease.
TLDR
It is concluded that adenovirus-mediated VEGF direct myocardial administration to patients with severe coronary artery disease is safe, and future larger trials are warranted to assess efficacy. Expand
Progress of Gene Therapy in Cardiovascular Disease
TLDR
The recent advances in proangiogenic gene therapy for critical limb ischemia and DNA vaccine for hypertension are discussed. Expand
Catheter-Based Intramyocardial Delivery (NavX) of Adenovirus Achieves Safe and Accurate Gene Transfer in Pigs
TLDR
Intramyocardial injection guided by NavX system provides a method of feasible and safe percutaneous gene transfer to myocardial infarct regions and shows a positive effect in patients with severe and diffused triple coronary disease. Expand
Effects of Adenovirus-Mediated Hepatocyte Growth Factor Gene Therapy on Postinfarct Heart Function: Comparison of Single and Repeated Injections.
TLDR
It is concluded that fractional repeated injections of Ad-HGF may represent a promising therapeutic strategy to improve cardiac function in the setting of postinfarct heart failure. Expand
HGF percutaneous endocardial injection induces cardiomyocyte proliferation and rescues cardiac function in pigs☆
TLDR
The over-expression of HGF activates pro-survival pathways, induces cardiomyocyte proliferation, and improves the perfusion and function of the porcine CMI heart. Expand
Novel therapy for myocardial infarction: can HGF/Met be beneficial?
TLDR
The mechanistic basis for autocrine and paracrine protection of HGF in the injured heart is described and the potential of the molecule for treating ischaemic heart disease in humans is discussed. Expand
Angiogenic gene therapy in cardiovascular diseases: dream or vision?
TLDR
The concept of angiogenic therapy as a sole treatment is re-evaluated and a combination with regenerative therapies or standard revascularization operations might be needed to improve tissue function and clinical benefits. Expand
In a Phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure.
TLDR
The data demonstrate the potential for autologous mesenchymal stem cell to increase blood flow, GFR and attenuate inflammatory injury in post-stenotic kidneys in ARVD. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 29 REFERENCES
Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease.
TLDR
The data are consistent with the concept that direct myocardial administration of Ad(GV)VEGF121.10 to individuals with clinically significant coronary artery disease appears to be well tolerated, and initiation of phase II evaluation of this therapy is warranted. Expand
Safety Evaluation of Clinical Gene Therapy Using Hepatocyte Growth Factor to Treat Peripheral Arterial Disease
TLDR
The initial clinical outcome with HGF gene transfer seems to indicate usefulness as sole therapy for CLI and safe and feasible injection of naked HGF plasmid DNA is safe, feasible, and can achieve successful improvement of ischemic limbs. Expand
Induction of collateral artery growth and improvement of post-infarct heart function by hepatocyte growth factor gene transfer
TLDR
High expression levels of human HGF were observed in the myocardium because of non-infarct-related vessel transfer, which can increase the number of functional arterioles and improve collateral artery growth and heart function. Expand
Gene transfer of hepatocyte growth factor improves angiogenesis and function of chronic ischemic myocardium in canine heart.
TLDR
Gene transfection of HGF improved angiogenesis, thereby improved regional myocardial function and perfusion in chronic ischemic myocardium, indicating a potent therapeutic value of H GF gene transfections for chronic isChemic heart diseases such as myocardIAL infarction. Expand
Angiogenic and antifibrotic actions of hepatocyte growth factor improve cardiac dysfunction in porcine ischemic cardiomyopathy
TLDR
Overall, the present in vivo experiments demonstrated that intramyocardial injection of human HGF plasmid DNA in ischemic cardiomyopathy resulted in a significant improvement in cardiac function through an increase in blood flow and decrease in fibrosis, suggesting potential utility to treat patients with isChemic heart disease using HGF gene transfer. Expand
Induction of Angiogenesis and Inhibition of Apoptosis by Hepatocyte Growth Factor Effectively Treats Postischemic Heart Failure
TLDR
Overexpression of HGF 3 weeks post‐MI resulted in enhanced angiogenesis, reduced apoptosis, greater preservation of ventricular geometry, and preservation of cardiac contractile function. Expand
Postinfarction Treatment With an Adenoviral Vector Expressing Hepatocyte Growth Factor Relieves Chronic Left Ventricular Remodeling and Dysfunction in Mice
TLDR
Postinfarction HGF gene therapy improved LV remodeling and dysfunction through hypertrophy of cardiomyocytes, infarct wall thickening, preservation of vessels, and antifibrosis. Expand
Therapeutic Angiogenesis: Protein and Gene Therapy Delivery Strategies
TLDR
The techniques available for providing therapeutic angiogenesis are described, including acute and sustained-release techniques to deliver protein angiogens and a number of gene therapy strategies to deliver genes coding for the angiogenic processes. Expand
Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease
TLDR
Overall, intramuscular injection of naked human HGF plasmid induced therapeutic angiogenesis in rat and rabbit ischemic hindlimb models, as potential therapy for peripheral arterial disease. Expand
Treatment of myocardial ischemia with bone marrow-derived mesenchymal stem cells overexpressing hepatocyte growth factor.
TLDR
Treatment of myocardial ischemia with bone marrow-derived mesenchymal stem cells overexpressing hepatocyte growth factor could be a novel strategy that can both restore local blood flow and regenerate lost cardiomyocytes. Expand
...
1
2
3
...